GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Polynovo Ltd (FRA:MFJ) » Definitions » Other Operating Expense

Polynovo (FRA:MFJ) Other Operating Expense : €3.97 Mil (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Polynovo Other Operating Expense?

Polynovo's Other Operating Expense for the six months ended in Dec. 2023 was €0.64 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was €3.97 Mil.

Polynovo's quarterly Other Operating Expense increased from Dec. 2022 (€0.63 Mil) to Jun. 2023 (€3.33 Mil) but then declined from Jun. 2023 (€3.33 Mil) to Dec. 2023 (€0.64 Mil).

Polynovo's annual Other Operating Expense increased from Jun. 2021 (€1.43 Mil) to Jun. 2022 (€2.60 Mil) and increased from Jun. 2022 (€2.60 Mil) to Jun. 2023 (€3.94 Mil).


Polynovo Other Operating Expense Historical Data

The historical data trend for Polynovo's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Polynovo Other Operating Expense Chart

Polynovo Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.76 1.15 1.43 2.60 3.94

Polynovo Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 2.10 0.63 3.33 0.64

Polynovo Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €3.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Polynovo Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Polynovo's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Polynovo (FRA:MFJ) Business Description

Traded in Other Exchanges
Address
320 Lorimer Street, Unit 2, Port Melbourne, VIC, AUS, 3207
Polynovo earns most of its revenue from U.S. sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.

Polynovo (FRA:MFJ) Headlines

No Headlines